EQL PHARMA Aktie

 

EQL Pharma CEO Axel Schörling has recently sold shares for approximately SEK 1.2 million to finance capital gains tax that arose upon redemption of the option program in September 2025. Axel Schörling has sold 24,066 shares and holds 389,892 shares in EQL Pharma after the sale. The sale corresponded to 5.8% of Schörling's total holdings....

In accordance with the instructions of the Nomination Committee in EQL Pharma, the Nomination Committee shall be convened by the Chairman of the Board and shall consist of a representative for each of the three largest shareholders in terms of votes who wish to appoint a Nomination Committee member. The composition of the Nomination Committee is based on shareholder statistics from Euroclear Sweden AB as of the last banking day in December and other reliable information on ownership that has been made known to the company at the same time. Based on the above, the Nomination Committee for the...

Today, on 3 February 2026, the extraordinary general meeting was held in EQL Pharma AB. A summary of the adopted resolution follows below. Resolution on implementation of a long-term incentive program The extraordinary general meeting resolved in accordance with the proposal from the board of directors to implement a long-term incentive program for two key employees based on issue of warrants.  The incentive program comprises a maximum of 220,000 warrants. Each warrant entitles the right to subscribe for one new share in the company at a subscription price per share corresponding to...

During the quarter, sales rose to SEK 118.9 million, an increase of 29% from SEK 92.2 million in the previous year. This represents a new record quarter for EQL Comments from the CEO The third quarter of 2025/26 marks a recovery for EQL Pharma. Sales growth of 29 percent and EBITDA grows by 44 percent. Gross and operating margins also strengthen to 42 and 21 percent, respectively. The majority of the stockouts from the second quarter have remained in the third. However, deliveries of Memprex have worked well, resulting in an overall stronger quarter. A gradually improved inventory...

EQL Pharma AB (publ) will publish its interim report for the third quarter, 2025/26, on Tuesday, February 3[rd]. At 10.00 (CET) 4[th] February, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/mpmbyxxn Date and time February 4[th], 2026, at 10.00 (CET) the...

The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the extraordinary general meeting to be held on Tuesday 3 February 2026 at 13.00 at the company's premises at Stortorget 1 in Lund. Right to participate and notification Shareholders wishing to attend the meeting must: · be registered in the company's share register kept by Euroclear Sweden AB as of Monday 26 January 2026, and · notify the company of their intention to participate in the meeting no later than Wednesday 28 January 2026 in writing by mail to EQL Pharma AB, Stortorget 1, SE-222 23 Lund....

As previously announced, EQL Pharma has decided to strengthen its abilities in international commercial affairs, as a part of its European expansion. The Company has recruited Anne D. Jensen for this role. Anne will join the team early March 2026 and the current Chief Commercial Officer, Alexander Brising, will, as previously announced, leave his position 31[st] December 2025. Additionally, Carl Lindgren will leave his position as CBDO in June 2026. Anne spent five years in the Boston Consulting Group (BCG)'s healthcare practice operating from the Los Angeles and Copenhagen offices. Since...

EQL Pharma strengthens and re-organizes its Finance Function to put more emphasis on business control and capital allocation. Our current CFO, Anna Jönsson, will take on the role as Head of Accounting. Allan Sylvest Aasberg will join as new CFO early April 2026. Allan has almost 25 years of experience from various finance roles in different types of organizations. His experience includes accounting, business control, group reporting, M&A, COO and CFO positions in large and small companies. He has worked in listed environment, family owned and PE owned firms and is used to the highest...

On 24 January 2025, EQL Pharma AB (publ) (the “Company”) issued senior secured bonds of SEK 350 million (the “Bonds”). The Bonds have been admitted to trading on the Transfer Market segment of Nasdaq First North Bond Market since 25 February 2025. In accordance with the terms and conditions of the Bonds, the Company has today submitted an application for admission to trading of the Bonds on the corporate bond list of Nasdaq Stockholm. The first day of trading in the Bonds on the corporate bond list of Nasdaq Stockholm is expected to be on or around 19 November 2025. In connection therewith,...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

EQL Pharma AB (publ) will publish its interim report for the second quarter, 2025/26, on Wednesday, November 5[th], before stock markets open. At 10.00 (CET) 5[th] November, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/yke7b4rd Date and time November 5[th],...

EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his position. Alexander has been active in EQL Pharma since 2016 and will remain in his role until the end of December 2025 and ensure a stable handover. - We would like to thank Alexander for his efforts over all these years, especially within the company's commercial strategies where he has worked to ensure that the portfolio of pharmaceutical products reaches its full potential in the geographical...

During September 2025, the number of shares and votes in EQL Pharma AB (“EQL Pharma”) has increased as a result of the exercise of warrants issued pursuant to two warrant programs adopted by the annual general meeting on 17 August 2021 and the extraordinary general meeting on 10 December 2021, respectively. As of 30 September 2025, the total number of shares and votes in EQL Pharma amounts to 29,529,610....

EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made up for in the third and fourth quarters. Full-year results for the 2025/26 financial year are expected to be closer to 15 than 30 percent growth. The delivery delays have also led to postponements of launches that were supposed to take place in Q2. These will instead take place towards the end of Q3 or early in Q4. As a result of the delivery delays, EQL Pharma announces that sales in the...

EQL Pharma's key product Mellozzan® (tablets) has been approved for sale by the Turkish Medicines Agency. EQL's partner in Turkey, Abdi Ibrahim, will both manufacture and market Mellozzan® locally. Sales are expected to commence in the first half of 2026. EQL receives a single-digit royalty based on sales. Mellozzan® in Turkey is expected to be expanded with the oral solution in 2027. The application is currently under review by the Turkish Medicines Agency. Abdi Ibrahim has also submitted an application for approval of Mellozzan® (tablets and oral solution) in Kazakhstan. About...

EQL Pharma AB (the ”Company“) today announces that two senior executives and one key employee in the Company have chosen to exercise 466,000 warrants in the Company's outstanding incentive programs for subscription of a total of 466,000 new shares. The Company's CEO as well as one senior executive and one key employee in the Company have chosen to make full use of the opportunity to subscribe for shares by exercise of warrants in the Company's long-term incentive programs 2021/2025 I and 2021/2021 II, respectively, which were resolved by the annual general meeting in August 2021 and the...

EQL Pharma's Chief Commercial Officer (CCO) Alexander Brising has recently sold shares for approximately SEK 2.1 million to pay for an apartment for his daughter who is starting university. "Not a decision I took lightly as I strongly believe in EQL where I have been a contributor to the success of the last nine years and I myself am one of the main authors of both previous plans and the new five-year plan. There are many exciting things in the pipeline. But the daughter could not find anywhere to live so it was not much of a choice in the end. Family has to come first." Alexander Brising...

Today, on 21 August 2025, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below. Resolution on adoption of accounts and allocation of the company's result The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and the consolidated balance sheet. The annual general meeting also resolved to distribute the company's result in accordance with the proposal from the board of directors in the annual report meaning that no dividends are paid for the financial year 2024/2025...

Ahead of the annual general meeting on 21 August 2025 in EQL Pharma AB, the Nomination Committee has presented its proposal regarding the election of the board of directors. The Nomination Committee proposes re-election of all board members except Per Ollermark, and the election of Raymond De Vré as a new member of the board. The Nomination Committee has consisted of Erik Hallengren, representing SEB Fonder, Christer Fåhraeus, representing Fårö Capital AB, and Rajiv I Modi, representing Cadila Pharmaceuticals Limited. For the annual general meeting, the Nomination Committee proposes:...

EQL Pharma AB (publ) will publish its interim report for the first quarter, 2025/26, on Friday, August 8[th], before stock markets open. At 10.00 (CET) 8[th] August, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate. Use the following link to access the virtual meeting: https://tinyurl.com/42kevwyk   Date and time August 8[th], 2025, at 10....